Realtree

Realta Life Sciences is a clinical-stage biotechnology company dedicated to developing a new class of therapies that address life-threatening inflammatory diseases. The company's proprietary platform focuses on dual-action mechanisms that simultaneously inhibit the complement system and Toll-like receptor 4 (TLR4) pathways to modulate the body's immune response. Its lead candidate, RLS-0071, is being evaluated in clinical trials for conditions such as hypoxic-ischemic encephalopathy (HIE) and acute exacerbations of COPD. By targeting the early drivers of inflammation, Realta aims to provide transformative treatments for patients with high unmet medical needs.